I think the point is simply that IV administration has not been established pre-clinically with any significance. Hence his first paragraph...
"I'm wondering if anyone has addressed the fact that there is limited preclinical evidence that has demonstrated a significant benefit from intravenous administration of CF33 either as a single agent or in combination with an anti-PDL1 in every murine model tested?"
Now if there is limited preclinical (animal) evidence of IV admin, then may not work in humans, through IV route.
The CF33, Vaxinia and Oncarlytics Deal, page-414
-
- There are more pages in this discussion • 674 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.001(0.88%) |
Mkt cap ! $420.8M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.8¢ | 5.6¢ | $869.4K | 15.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 223103 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 587686 | 18 |
View Market Depth
| Last trade - 14.49pm 26/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |